ScholarIQanswers from OpenAlex
Novo Nordisk Pharma
FunderResearch funding and supported work
Novo Nordisk Pharma is a funder indexed in ScholarIQ from OpenAlex.
How many works does Novo Nordisk Pharma have?
ScholarIQindexed works
Novo Nordisk Pharma has 869 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Novo Nordisk Pharma?
ScholarIQopenalex
The OpenAlex for Novo Nordisk Pharma is on the source record.
What are the most-cited papers on Novo Nordisk Pharma?
ScholarIQmost cited works
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt‐Lindberg, G. Kees Hovingh, Steven E. Kahn, Robert F. Kushner, Ildiko Lingvay, Tuğçe Kalaycı Oral, Marie Mide Michelsen, Jorge Plutzky, Christoffer W. Tornøe, Donna H. Ryan
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, John Deanfield, Kirstine Brown‐Frandsen, Steven E. Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John Wilding, Johannes F.E. Mann, Katherine R. Tuttle, Thomas Idorn, Naveen Rathor, A. Michael Lincoff